Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 4:46 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 183 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Anti-TNF Clear all

Conditions: Rheumatoid Arthritis
Interventions: Leflunomide, Methotrexate, Ocrelizumab, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 836 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2018
U.S. locations: 144
States / cities: Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 116 more

Conditions: Rheumatoid Arthritis
Interventions: Tumor Necrosis Factor Inhibitors, Abatacept; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 63,013 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Ulcerative Colitis
Interventions: Adalimumab; Biological
Lead sponsor: AbbVie; Industry
Eligibility: 4 Years to 17 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 4
States / cities: Orlando, Florida • Minneapolis, Minnesota • Rochester, Minnesota + 1 more

Conditions: Non Small Cell Lung Cancer, Lung Cancer
Interventions: FLT3 Ligand (CDX-301), anti-CD40 antibody (CDX-1140), SBRT; Drug · Biological · Radiation
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Inflammatory Bowel Diseases
Interventions: Serial Biopsy; Procedure
Lead sponsor: Terrence A Barrett; Other
Eligibility: 18 Years to 90 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Crohn's Disease
Interventions: MEDI2070, placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 26
States / cities: Encinitas, California • Los Angeles, California • San Diego, California + 22 more

Conditions: Arthritis, Rheumatoid
Interventions: Placebo, Sirukumab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 878 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 81
States / cities: Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 78 more

Conditions: Herpes Zoster, Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
Interventions: Not listed
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 35 Years to 49 Years
Enrollment: 97 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Rheumatoid Arthritis
Interventions: sarilumab SAR153191 (REGN88), tocilizumab, hydroxychloroquine, methotrexate, sulfasalazine, leflunomide, subcutaneous placebo, intravenous placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 14
States / cities: Huntsville, Alabama • Colorado Springs, Colorado • Aventura, Florida + 10 more

Conditions: Rheumatoid Arthritis
Interventions: Certolizumab Pegol (CZP), Arthroscopic synovial tissue biopsy; Drug · Procedure
Lead sponsor: Nathan Wei, MD, FACP, FACR:; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Frederick, Maryland

Conditions: Ulcerative Colitis (UC), Crohn Disease (CD)
Interventions: Mirikizumab, Anti-TNF agents, anti-integrin antibodies, IL-12, IL-23; Drug
Lead sponsor: Specialty Networks Research.; Network
Eligibility: 21 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 13
States / cities: Sun City, Arizona • Tucson, Arizona • Glenview, Illinois + 10 more

Conditions: Pancreatitis, Chronic; Diabetes; Transplant
Interventions: etanercept, Alpha 1-Antitrypsin; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 65 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Rheumatoid Arthritis
Interventions: Andecaliximab, Placebo, Methotrexate, TNF Inhibitor; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 8
States / cities: Palo Alto, California • DeBary, Florida • Las Vegas, Nevada + 5 more

Conditions: Psoriatic Arthritis
Interventions: Human anti-TNF monoclonal antibody/adalimumab; Biological
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Abbott Park, Illinois

Conditions: Sciatica, Herniated Disc, Radiculopathy
Interventions: REN-1654; Drug
Lead sponsor: Renovis; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 19
States / cities: Birmingham, Alabama • Tuscon, Arizona • Stanford, California + 15 more

Conditions: Spondylitis, Ankylosing
Interventions: Anti-Tumor Necrosis Factor; Drug
Lead sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2002
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Crohn Disease
Interventions: JNJ-64304500, Placebo, Adalimumab, Ustekinumab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Rheumatoid Arthritis
Interventions: Tofacitinib, TNF Inhibitor; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 105,711 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Rheumatoid Arthritis
Interventions: Infliximab; Drug
Lead sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); NIH
Eligibility: Not listed
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Colitis, Ulcerative, Inflammatory Bowel Diseases, Crohn's Disease
Interventions: No intervention; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 9,573 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Rheumatoid Arthritis, Tuberculosis
Interventions: Not listed
Lead sponsor: Walter Reed Army Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Crohn's Disease
Interventions: CROWN, CROWN Placebo; Drug
Lead sponsor: Prometheus Laboratories; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 39
States / cities: Dothan, Alabama • Huntsville, Alabama • Little Rock, Arkansas + 34 more

Conditions: Arthritis, Rheumatoid
Interventions: Not listed
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 30
States / cities: Murrieta, California • Longmont, Colorado • Lewes, Delaware + 27 more

Conditions: Rheumatoid Arthritis
Interventions: Adalimumab; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 54
States / cities: Mobile, Alabama • Apple Valley, California • Bakersfield, California + 50 more

Search by objective public record fields.

A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT)

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - TNFi vs Abatacept

Long-term Safety and Efficacy Study of Adalimumab in Pediatric Subjects With Ulcerative Colitis

FLT3 Ligand, CD40 Agonist Antibody, and Stereotactic Radiotherapy

Regulation of Mucosal Healing in Inflammatory Bowel Disease

Evaluation of Efficacy and Safety of MEDI2070 in Patients With Active, Moderate-to-severe Crohn's Disease.

A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND-T)

Identifying Young Inflammatory Bowel Disease Patients at Risk for Herpes Zoster

To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)

Rheumatoid Arthritis Treatment and Biopsy Study Assessing Certolizumab Pegol (Cimzia)

INSIGHT-IBD Pragmatic Study

Anti-inflammatory Therapy to Improve Outcomes After TPIAT

Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis

Safety and Efficacy of Adalimumab in Patients With Moderate to Severely Active Psoriatic Arthritis

Study of REN-1654 in Patients With Sciatica Pain

Blocking Tumor Necrosis Factor in Ankylosing Spondylitis

A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease

Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)-Cancer Endpoints

Infliximab for the Treatment of Early Rheumatoid Arthritis

Patient Attitudes and Preferences for Outcomes of Inflammatory Bowel Disease Therapeutics

Comparison of the Tuberculin Skin Test (TST) and QuantiFERON ®-TB Gold Test (QFT-G) In Patients With Rheumatoid Arthritis Being Considered for Anti-TNF-Alpha Therapy

Efficacy of CROWN in Repair and Maintenance of the Intestinal Mucosa in Patients With CD Receiving Anti-TNF Therapy

Biomarkers of Anti-TNF-α Therapy Efficacy in Rheumatoid Arthritis to Define Unresponsive Patients

Study of Human Anti-TNF Monoclonal Antibody D2E7 in Subjects With Active Rheumatoid Arthritis